Trials / Completed
CompletedNCT04829305
A Trial of SHR2285 in Healthy Subjects
A Phase 1, Single Center, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR2285 Single Oral Administration in Healthy Caucasian Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Atridia Pty Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This is a phase 1 open-label study
Detailed description
This is a phase 1 open-label study. The objective of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of oral administered SHR2285 in healthy subjects
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR2285 | SHR2285 is a selective inhibition of human FXIa small molecule compound. |
Timeline
- Start date
- 2021-05-20
- Primary completion
- 2021-09-06
- Completion
- 2021-09-06
- First posted
- 2021-04-02
- Last updated
- 2022-03-08
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT04829305. Inclusion in this directory is not an endorsement.